Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...
Stocktwits on MSN
Johnson & Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive Disorder
The new approval is the first for the drug under JNJ leadership. ・The drug is also approved for the treatment of bipolar I ...
The expanded indication for the oral atypical antipsychotic now includes adjunctive use with antidepressants in adults with major depressive disorder.
Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
MedPage Today on MSN
FDA Broadens Caplyta Approval to Include Major Depression
The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...
Please provide your email address to receive an email when new articles are posted on . Spravato is the first monotherapy for adults with major depressive disorder who had an inadequate response to at ...
Moment of Clarity has published a new educational resource titled “Acccelerated TMS Therapy for Depression“, providing an ...
SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational study to evaluate the efficacy, safety and tolerability ...
News-Medical.Net on MSN
GeneSight test-guided treatment leads to faster remission and response in patients with depression
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback